Merit Medical Systems - MMSI Stock Forecast, Price & News

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Merit Medical Systems Trading Up 0.4 %

NASDAQ:MMSI traded up $0.22 during trading on Tuesday, hitting $60.90. The company had a trading volume of 9,745 shares, compared to its average volume of 395,058. The company has a current ratio of 2.52, a quick ratio of 1.33 and a debt-to-equity ratio of 0.22. Merit Medical Systems has a one year low of $50.46 and a one year high of $73.85. The company has a market cap of $3.45 billion, a price-to-earnings ratio of 59.49, a price-to-earnings-growth ratio of 2.20 and a beta of 1.02. The company's fifty day moving average is $55.69 and its 200-day moving average is $59.77.

Merit Medical Systems (NASDAQ:MMSI - Get Rating) last issued its quarterly earnings data on Wednesday, July 27th. The medical instruments supplier reported $0.73 EPS for the quarter, topping the consensus estimate of $0.58 by $0.15. Merit Medical Systems had a net margin of 5.24% and a return on equity of 13.74%. The business had revenue of $294.98 million during the quarter, compared to analyst estimates of $280.55 million. During the same period in the prior year, the business earned $0.62 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis. On average, sell-side analysts predict that Merit Medical Systems will post 2.48 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on MMSI shares. Barrington Research dropped their price target on shares of Merit Medical Systems from $82.00 to $78.00 in a research report on Thursday, April 28th. Piper Sandler dropped their price target on shares of Merit Medical Systems from $75.00 to $70.00 in a research report on Friday, July 1st. TheStreet cut shares of Merit Medical Systems from a "b-" rating to a "c+" rating in a research report on Wednesday, May 11th. StockNews.com raised shares of Merit Medical Systems from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, April 13th. Finally, Canaccord Genuity Group dropped their price target on shares of Merit Medical Systems from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Monday, August 1st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $72.33.

Insider Buying and Selling

In related news, Director F. Ann Millner sold 6,378 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $61.92, for a total value of $394,925.76. Following the completion of the transaction, the director now directly owns 27,698 shares in the company, valued at approximately $1,715,060.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director F. Ann Millner sold 6,378 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $61.92, for a total value of $394,925.76. Following the completion of the transaction, the director now directly owns 27,698 shares in the company, valued at approximately $1,715,060.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Neil Peterson sold 4,000 shares of the firm's stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $58.10, for a total transaction of $232,400.00. The disclosure for this sale can be found here. 3.80% of the stock is owned by company insiders.